Insmed Incorporated INSM

INSM Company Overview

Insmed Incorporated is a U.S.-based biopharmaceutical company focused on the development and commercialization of therapies for patients with serious and rare diseases, particularly in pulmonary and inflammatory conditions. The company operates primarily within the biotechnology and specialty pharmaceuticals industries and generates revenue principally from the commercialization of ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibiotic approved for treatment-refractory Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen. Insmed’s broader pipeline includes investigational therapies targeting pulmonary arterial hypertension, bronchiectasis, and inflammatory diseases. The company serves specialty healthcare providers, hospitals, and patients with orphan and underserved medical conditions across multiple global markets.

Founded in 1988, Insmed evolved from an early-stage biotechnology company into a commercial-stage rare disease organization following the regulatory approval and launch of ARIKAYCE in the United States and other international markets. The company has increasingly concentrated its strategy on respiratory and rare disease therapeutics, leveraging proprietary delivery technologies and targeted clinical development programs. Its positioning is supported by orphan drug expertise, regulatory experience in niche indications, and established relationships with pulmonologists and specialty treatment centers.